These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19362667)

  • 21. The spurious advance of antipsychotic drug therapy.
    Tyrer P; Kendall T
    Lancet; 2009 Jan; 373(9657):4-5. PubMed ID: 19058841
    [No Abstract]   [Full Text] [Related]  

  • 22. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 23. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of methodology on outcomes of randomised clozapine trials.
    Wahlbeck K; Tuunainen A; Gilbody S; Adams CE
    Pharmacopsychiatry; 2000 Mar; 33(2):54-9. PubMed ID: 10761820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Atypical neuroleptics--a heterogenous group. Valuable option in acute psychoses].
    MMW Fortschr Med; 2002 May; Suppl 2():85. PubMed ID: 12070863
    [No Abstract]   [Full Text] [Related]  

  • 26. A profile analysis approach using MMRM in acute schizophrenia: a comparison to some traditional approaches.
    Stiger TR; Banerjee A
    J Biopharm Stat; 2013; 23(6):1372-82. PubMed ID: 24138437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials.
    Matsuda Y; Kishi T; Iwata N
    J Psychiatr Res; 2013 Dec; 47(12):2018-20. PubMed ID: 24079776
    [No Abstract]   [Full Text] [Related]  

  • 28. Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials.
    Sarin F; Wallin L; Widerlöv B
    Nord J Psychiatry; 2011 Jun; 65(3):162-74. PubMed ID: 21563994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia: a 100-year retrospective.
    Warner R
    Am J Psychiatry; 1995 Nov; 152(11):1693; author reply 1694-5. PubMed ID: 7485646
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia.
    Citrome L
    Int J Clin Pract; 2008 May; 62(5):837-40. PubMed ID: 18412940
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comment with the (age-) psychiatric viewpoint].
    Stoppe G
    Praxis (Bern 1994); 2009 Oct; 98(21):1225-7. PubMed ID: 19844881
    [No Abstract]   [Full Text] [Related]  

  • 33. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review: The biological basis of antipsychotic response in schizophrenia.
    Stone JM; Raffin M; Morrison P; McGuire PK
    J Psychopharmacol; 2010 Jul; 24(7):953-64. PubMed ID: 19939865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antipsychotic drug combinations in the treatment of schizophrenia. A review of the literature].
    Gazdag G; Tolna J; Bitter I
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):189-95. PubMed ID: 22987732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
    Fusar-Poli P; Kempton MJ; Rosenheck RA
    Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
    Song F; Harvey I; Lilford R
    J Clin Epidemiol; 2008 May; 61(5):455-63. PubMed ID: 18394538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia.
    Jaffe AB; Levine J
    J Clin Psychiatry; 2003; 64 Suppl 17():3-6. PubMed ID: 14680419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes similar with first- and second-generation antipsychotics.
    Seidlinger J; Provost GP
    Am J Health Syst Pharm; 2006 Nov; 63(22):2172, 2175. PubMed ID: 17090731
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing the robustness of direct meta-analysis in the presence of heterogeneity.
    Ainsworth C
    J Comp Eff Res; 2018 Oct; 7(10):1009-1025. PubMed ID: 30130972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.